Hydroxychloroquine in IgA nephropathy: a systematic review

References

• Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414.
   PubMed Web of Science ®Google Scholar
• D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709–727.
   PubMedGoogle Scholar
• Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9(3):265–269.
   PubMed Web of Science ®Google Scholar
• Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751–760.
   PubMed Web of Science ®Google Scholar
• Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225–2236.
   PubMed Web of Science ®Google Scholar
• Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(2):268–280.
   PubMedGoogle Scholar
• Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. Jama. 2017;318(5):432–442.
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117–2127.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. 2013;43(2):264–272.
   PubMed Web of Science ®Google Scholar
• Gao R, Wu W, Wen Y, et al. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. Int Urol Nephrol. 2017;49(7):1233–1241.
   PubMed Web of Science ®Google Scholar
• Liu LJ, Yang YZ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15–22.
   PubMed Web of Science ®Google Scholar
• Tang C, Lv JC, Shi SF, et al. Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study. BMC Nephrol. 2020;21(1):469.
   PubMed Web of Science ®Google Scholar
• Yang YZ, Chen P, Liu LJ, et al. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. 2019;20(1):297.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated february 2021). Cochrane. 2021.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–196.
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, A Inker L, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481.
   PubMed Web of Science ®Google Scholar
• Gutierrez E, Carvaca-Fontan F, Luzardo L, et al. A personalized update on IgA nephropathy: a new vision and new future challenges. Nephron. 2020;144(11):555–571.
   PubMed Web of Science ®Google Scholar
• Tang C, Lv JC, Shi SF, et al. Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience. J Nephrol. 2021.DOI:10.1007/s40620-021-00988-1.
   Web of Science ®Google Scholar
• Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435–1455.
   PubMed Web of Science ®Google Scholar
• Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat Rev Mol Cell Biol. 2020;21(2):101–118.
   PubMed Web of Science ®Google Scholar
• Robert T, Berthelot L, Cambier A, et al. Molecular insights into the pathogenesis of IgA nephropathy. Trends Mol Med. 2015;21(12):762–775.
   PubMed Web of Science ®Google Scholar
• Makita Y, Suzuki H, Kano T, et al. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340–349.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166.
   PubMed Web of Science ®Google Scholar
• Ewald SE, Lee BL, Lau L, et al. The ectodomain of toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456(7222):658–662.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794–4804.
   PubMed Web of Science ®Google Scholar
• van den Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55–60.
   PubMed Web of Science ®Google Scholar
• Shu KH, Lee SH, Cheng CH, et al. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy. Kidney Int. 2000;58(2):783–789.
   PubMed Web of Science ®Google Scholar
• Jallouli M, Frances C, Piette JC, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol. 2013;149(8):935–940.
   PubMed Web of Science ®Google Scholar
• Soria A, Barbaud A, Assier H, et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology. 2015;231(4):353–359.
   PubMed Web of Science ®Google Scholar
• Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. Clin Exp Dermatol. 2008;33(5):572–574.
   PubMed Web of Science ®Google Scholar
• Angelakis E, Million M, Kankoe S, et al. Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob Agents Chemother. 2014;58(6):3342–3347.
   PubMed Web of Science ®Google Scholar
• Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77–83.
   PubMedGoogle Scholar
• Jorge A, Ung C, Young LH, et al. Hydroxychloroquine retinopathy: implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14(12):693–703.
   PubMed Web of Science ®Google Scholar
• Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–1460.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the joint European league against rheumatism and European renal Association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713–723.
   PubMed Web of Science ®Google Scholar